Enzolytics Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Enzolytics Inc., founded in 1980 and headquartered in Plano, Texas, is a biotechnology company specializing in the development and commercialization of proprietary therapeutic proteins and monoclonal antibody therapies for the treatment of debilitating infectious diseases. The company’s core products include anti-HIV therapeutics such as ITV-1, which has undergone clinical testing, and a proprietary cell line technology that produces fully human IgG1 monoclonal antibodies targeting viruses including HIV, SARS-CoV-2, rabies, influenza, tetanus, and diphtheria. Enzolytics also develops immune system modulators and nutraceutical products, with its IPF Immune™ immune booster marketed under U.S. patent protection. The company's operations span research and development, drug discovery using artificial intelligence, manufacturing, and commercialization activities primarily in the United States with plans for international deployment including Africa and Europe. Recent strategic developments include an exclusive worldwide licensing agreement for a patented immunotherapy cancer treatment (U.S. Patent #8,067,531-B2), a Letter of Intent with Enogenesis to license a patented Nitric Oxide Compound for therapeutic use, and partnerships such as the end-to-end CDMO services agreement with Samsung Biologics for advancing its monoclonal antibodies into IND filings. Enzolytics formed ETC Marketing Inc. in collaboration with Third Coast Fulfillment to expand into licensing and digital marketing of medical devices, nutraceuticals, and health products, enhancing consumer engagement and distribution channels. Additionally, the company is progressing toward acquiring a GMP-standard pharmaceutical manufacturing facility in Bulgaria and has resolved multiple legacy litigations, allowing focused growth and innovation. Enzolytics maintains subsidiaries including BioClonetics Immunotherapy, Inc. and Biogenysis, Inc., and continues to leverage its artificial intelligence platform for early drug discovery, intellectual property development, and personalized medicine entry.
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.
Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada
Update on Formulation of New Business Strategy
Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity
Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
Biogenysis' International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes